Loading
5 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Serum tryptase, KIT D816V testing in peripheral blood, bone marrow biopsy with flow cytometry, tryptase gene copy number, bone density scan and screening for B and C findings.
Histopathology means looking at cancer cells under a microscope, and immunohistochemistry stains them for specific proteins. Together they are still the foundation of every diagnosis.
Flow cytometry MRD counts leukaemia cells in the bone marrow one at a time by their surface proteins, down to one in ten thousand.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
H1 and H2 antihistamines, cromoglicate, leukotriene antagonists, proton-pump inhibitors; omalizumab for recurrent anaphylaxis; adrenaline autoinjectors for all; venom immunotherapy after sting anaphylaxis; bisphosphonates for osteoporosis.
Patients report symptoms weekly through an app or web form, and nurses respond to alerts. Randomised trials showed this simple system improved quality of life, cut emergency visits and, in one trial, extended survival by five months.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Avapritinib 25 mg daily (PIONEER, approved 2023), avoided when platelets are below 50 x 10^9/L; cladribine or interferon alfa as older cytoreductive options.
Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis.
A one-week infusion that puts most people with hairy cell leukaemia into remission for years; also used in multiple sclerosis in tablet form.
Interferon alfa was the first biologic cancer drug (1986). It treated hairy cell leukaemia, CML, melanoma, kidney cancer and Kaposi sarcoma, and has been replaced almost everywhere by better-tolerated agents.
Pills that block the specific enzyme a cancer relies on. Imatinib in 2001 proved a cancer could be switched off by design.
No headline result recorded yet.
Add these to your appointment list, or take the full question set for this cancer.
Elenestinib (HARBOR) and bezuclastinib (Summit) as more selective KIT D816V inhibitors.
Elenestinib is an experimental small-molecule drug from Blueprint Medicines in phase 3 trials for systemic mastocytosis, with its target not yet stated publicly.
Bezuclastinib is an experimental small-molecule drug from Cogent Biosciences in phase 3 trials for gastrointestinal stromal tumour, aimed at KIT and MET.
No headline result recorded yet.
No headline result recorded yet.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
Add these to your appointment list, or take the full question set for this cancer.
Tryptase, KIT allele burden and blood count yearly; bone density; marrow re-examination only if progression is suspected.
A blood test that reads fragments of DNA shed by the tumour, so you can genotype or monitor cancer without a needle in the tumour.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.